文献速递核素与放射性配体治疗

对200例晚期转移性神经内分泌肿瘤患者进行177Lu-DOTA-奥曲肽治疗的前瞻性观察研究:剂量学指导研究方案的可行性及其对结局和毒性的影响

Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2018-03-01

该前瞻性观察研究纳入200例连续晚期转移性生长抑素受体阳性神经内分泌肿瘤患者,每周期给予7.4 GBq 177Lu-DOTA-奥曲肽直至肾脏吸收剂量达23 Gy。123例(61.5%)达到肾脏23 Gy,最佳反应为完全缓解1例(0.5%)、部分缓解47例(23.5%)、疾病稳定135例(67.5%)、疾病进展7例(3.5%);全组中位无进展生存期27个月(95%CI 22-30个月),中位总生存期43个月(95%CI 39-53个月)。

要点

  • 肾脏吸收剂量达23 Gy者中位总生存期54个月,未达者25个月。
  • 最佳反应为部分缓解或完全缓解者中位总生存期60个月,疾病稳定者42个月,疾病进展者16个月。
  • 3例(1.5%)发生急性白血病,30例(15%)发生3或4级骨髓毒性,骨髓剂量学未预测毒性。

核心结论

  • 基于剂量学的177Lu-DOTA-奥曲肽治疗是可行的。
  • 肾脏吸收剂量达到23 Gy的患者总生存期长于未达到者。
  • 完全缓解或部分缓解患者的总生存期长于疾病稳定患者。
  • 骨髓剂量学未预测毒性。

研究设计与样本

  • 前瞻性观察研究,纳入200例连续转移性生长抑素受体阳性神经内分泌肿瘤患者,标准治疗进展或不适合其他治疗选择。
  • 每周期给予7.4 GBq 177Lu-DOTA-奥曲肽并联合输注混合氨基酸溶液,重复周期直至肾脏吸收剂量达23 Gy或有其他停止治疗原因。
  • Ki-67指数≤2%者47例(23.5%),3-20%者121例(60.5%),>20%者16例(8%)。

主要发现

  • 123例(61.5%)在一线治疗期间经3至9个周期肾脏吸收剂量达到23 Gy;无患者骨髓吸收剂量达到2 Gy。
  • 最佳反应(RECIST 1.1):完全缓解1例(0.5%),部分缓解47例(23.5%),疾病稳定135例(67.5%),疾病进展7例(3.5%)。
  • 全组中位无进展生存期27个月(95%CI 22-30个月),肾脏吸收剂量达23 Gy者33个月,未达者15个月。
  • 全组中位总生存期43个月(95%CI 39-53个月),肾脏吸收剂量达23 Gy者54个月,未达者25个月。
  • 中位总生存期在最佳反应为部分缓解或完全缓解者中为60个月,疾病稳定者42个月,疾病进展者16个月。

关键数值与推荐

  • 每周期177Lu-DOTA-奥曲肽剂量为7.4 GBq,联合混合氨基酸溶液输注。
  • 治疗重复直至肾脏吸收剂量达23 Gy或有其他停止治疗原因。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Peptide receptor radionuclide therapy in patients with neuroendocrine tumours has yielded promising results. This prospective study investigated the feasibility of dosimetry of the kidneys and bone marrow during therapy and its impact on efficacy and outcome. METHODS: The study group comprised 200 consecutive patients with metastasized somatostatin receptor-positive neuroendocrine tumours progressing on standard therapy or not suitable for other therapeutic options. A treatment cycle consisted of 7.4 GBq 177Lu-DOTA-octreotate with co-infusion of a mixed amino acid solution, and cycles were repeated until the absorbed dose to the kidneys reached 23 Gy or there were other reasons for stopping therapy. The Ki-67 index was ≤2% in 47 patients (23.5%), 3-20% in 121 (60.5%) and >20% in 16 (8%). RESULTS: In 123 patients (61.5%) the absorbed dose to the kidneys reached 23 Gy with three to nine cycles during first-line therapy; in no patient was a dose to the bone marrow of 2 Gy reached. The best responses (according to RECIST 1.1) were a complete response (CR) in 1 patient (0.5%), a partial response (PR) in 47 (23.5%), stable disease (SD) in 135 (67.5%) and progressive disease (PD) in 7 (3.5%). Median progression-free survival was 27 months (95% CI 22-30 months) in all patients, 33 months in those in whom the absorbed dose to the kidneys reached 23 Gy and 15 months in those in whom it did not. Median overall survival (OS) was 43 months (95% CI 39-53 months) in all patients, 54 months in those in whom the absorbed dose to the kidneys reached 23 Gy and 25 months in those in whom it did not. Median OS was 60 months in patients with a best response of PR or CR, 42 months in those with SD and 16 months in those with PD. Three patients (1.5%) developed acute leukaemia, 1 patient (0.5%) chronic leukaemia (unconfirmed) and 30 patients (15%) grade 3 or 4 bone marrow toxicity. Eight patients (4%) developed grade 2 kidney toxicity and one patient (0.5%) grade 4 kidney toxicity. CONCLUSIONS: Dosimetry-based therapy with 177Lu-DOTA-octreotate is feasible. Patients in whom the absorbed dose to the kidneys reached 23 Gy had a longer OS than those in whom it did not. Patients with CR/PR had a longer OS than those with SD. Bone marrow dosimetry did not predict toxicity.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Garske-Román U, Sandström M, Fröss Baron K, et al. Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity. Eur J Nucl Med Mol Imaging. 2018. PMID: 29497803. doi:10.1007/s00259-018-3945-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。